INT183207

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.18
First Reported 2003
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 14
Total Number 16
Disease Relevance 10.97
Pain Relevance 4.00

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

vesicle-mediated transport (USE1) endoplasmic reticulum (USE1) lysosome (USE1)
Anatomy Link Frequency
proximal 2
plasma 1
liver 1
USE1 (Homo sapiens)
Pain Link Frequency Relevance Heat
COX2 128 100.00 Very High Very High Very High
Pain 97 100.00 Very High Very High Very High
agonist 34 100.00 Very High Very High Very High
Neuropathic pain 8 100.00 Very High Very High Very High
antagonist 6 100.00 Very High Very High Very High
Infliximab 130 99.84 Very High Very High Very High
Mcgill questionnaire 2 97.60 Very High Very High Very High
Pain score 2 96.70 Very High Very High Very High
fibrosis 42 95.88 Very High Very High Very High
cINOD 89 94.68 High High
Disease Link Frequency Relevance Heat
INFLAMMATION 176 100.00 Very High Very High Very High
Pain 132 100.00 Very High Very High Very High
Neuropathic Pain 22 100.00 Very High Very High Very High
Diabetes Mellitus 120 99.84 Very High Very High Very High
Onchocerciasis 17 99.36 Very High Very High Very High
Toxicity 8 99.04 Very High Very High Very High
Myocardial Infarction 68 98.72 Very High Very High Very High
Colon Cancer 8 98.52 Very High Very High Very High
Stress 10 98.50 Very High Very High Very High
Autoimmune Disease 2 97.88 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The profile for cluster 4 is our referent cluster and we are naming it “Low Use” because it shows low use of all services.
Negative_regulation (shows) of low use
1) Confidence 0.18 Published 2008 Journal AIDS Behav Section Body Doc Link PMC2834767 Disease Relevance 0.53 Pain Relevance 0
At that time, it was debated whether this difference in CV risk was the result of a protective effect of naproxen on the incidence of MI (Bombardier et al 2000), or a consequence (side-effect) of the use of COX2 inhibitors.
Negative_regulation (inhibitors) of use associated with cox2 and myocardial infarction
2) Confidence 0.09 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504080 Disease Relevance 1.42 Pain Relevance 0.31
In the complex clinical context of efficiency and safety of selective and non-selective COX inhibitors, the prescription and use of COX2 inhibitors should be based on the risk and safety profile of the patient.
Negative_regulation (inhibitors) of use associated with cox2
3) Confidence 0.09 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504080 Disease Relevance 0.91 Pain Relevance 0.58
It has been suggested that COX2 is up regulated in vascular segments under conditions of increased vascular shear stress, and that the reduction of endovascular production of prostacyclin by the use of COX2 inhibitors induces an elevated risk of vascular thrombotic events (Solomon 2005).
Negative_regulation (inhibitors) of use associated with stress and cox2
4) Confidence 0.09 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504080 Disease Relevance 1.14 Pain Relevance 0.35
Later on, in studies developed to observe whether the use of COX2 inhibitors protected against the occurrence of colonic polyps, it has become clear that rofecoxib, as compared to placebo, doubles the risk for thrombotic events, mainly myocardial infarction and ischemic CV events (Bresalier et al 2005; Kerr et al 2007).
Spec (whether) Negative_regulation (inhibitors) of use associated with colon cancer, cox2 and myocardial infarction
5) Confidence 0.09 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504080 Disease Relevance 1.41 Pain Relevance 0.30
The use of H2-receptor antagonists and/or proton pump inhibitors also did not lead to significant differences in the incidence of these events between risedronate and placebo groups.
Negative_regulation (inhibitors) of use associated with antagonist
6) Confidence 0.05 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2909499 Disease Relevance 0.09 Pain Relevance 0.19
In the extension study of the original phase III trial in adult patients, pain scores as measured by the McGill Pain Questionnaire improved over time with sustained agalsidase beta treatment at 1 mg/kg EOW for those who reported pain at baseline and use of pain medications was reduced in some patients [309,329].
Negative_regulation (reduced) of use associated with pain, pain score and mcgill questionnaire
7) Confidence 0.04 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC3009617 Disease Relevance 0.85 Pain Relevance 0.61
In two pediatric clinical trials of ERT with agalsidase alfa, including 37 children [342,343], boys demonstrated reductions in plasma Gb3 levels, and both boys and girls reported reductions in neuropathic pain and in the use of neuropathic pain medications.
Negative_regulation (reductions) of use in plasma associated with neuropathic pain
8) Confidence 0.04 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC3009617 Disease Relevance 0.70 Pain Relevance 0.25
For gadodiamide (Omniscan®) :Gadodiamide is contraindicated in patients with severe renal impairment (GFR < 30 ml/min per 1.73 m2), and those who have had or are undergoing liver transplantationSpecial warnings and precautions for use:Severe renal impairment and liver transplant patients:There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of gadodiamide and some other gadolinium-containing contrast agents in patients with severe renal impairment (GFR < 30 ml/min per 1.73 m2) and those who have had or are undergoing liver transplantation.
Negative_regulation (undergoing) of use in liver associated with nephrogenic fibrosing dermopathy and fibrosis
9) Confidence 0.03 Published 2007 Journal MAGMA Section Body Doc Link PMC2797854 Disease Relevance 0.33 Pain Relevance 0.16
Besides immunogenicity, several other factors limit the use of infliximab, such as toxicity, cardiovascular and autoimmune disorders, demyelinating disease, and a 1% mortality rate, reported in 500 patients after a median follow-up of 17 (range, 0–48) months (Colombel et al. 2004).
Negative_regulation (limit) of use associated with toxicity, autoimmune disease, infliximab and demyelinating disease
10) Confidence 0.03 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 1.36 Pain Relevance 0.48
The therapeutic use of murine mAbs in humans is considerably limited by issues relating to immunogenicity.
Negative_regulation (limited) of use
11) Confidence 0.03 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 0.24 Pain Relevance 0.42
The USE 1,2 mut was prepared using COX-2 proximal wild-type DNA template in the PCR, while the USE 1,2,3 mut was prepared using USE 3 mut DNA template.
Negative_regulation (prepared) of USE 1,2 in proximal
12) Confidence 0.02 Published 2005 Journal Nucleic Acids Research Section Body Doc Link PMC1088970 Disease Relevance 0 Pain Relevance 0
The USE 1,2 mut was prepared using COX-2 proximal wild-type DNA template in the PCR, while the USE 1,2,3 mut was prepared using USE 3 mut DNA template.
Negative_regulation (prepared) of USE 1,2,3 in proximal
13) Confidence 0.02 Published 2005 Journal Nucleic Acids Research Section Body Doc Link PMC1088970 Disease Relevance 0 Pain Relevance 0
The reference lists of appropriate studies and review articles were reviewed for additional sources regarding the use of PRP and rhPDGF-BB.


Negative_regulation (regarding) of use
14) Confidence 0.02 Published 2010 Journal The Yale Journal of Biology and Medicine Section Body Doc Link PMC2844688 Disease Relevance 0.86 Pain Relevance 0
Given the comparable outcomes of the use of GLP-1 agonists and DPP-4 inhibitors in T2DM for many parameters, their cost-effectiveness is an important issue.
Negative_regulation (inhibitors) of use associated with diabetes mellitus and agonist
15) Confidence 0.02 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731024 Disease Relevance 0.49 Pain Relevance 0.08
Mectizan® has eliminated the use of DEC (except as a diagnostic agent in the "patch test") and left little justification for the use of suramin.
Negative_regulation (eliminated) of use
16) Confidence 0.01 Published 2003 Journal Filaria J Section Body Doc Link PMC2147654 Disease Relevance 0.63 Pain Relevance 0.27

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox